How edoxaban works in adults with nephrotic syndrome
Treatments studied
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how a blood thinner called edoxaban is processed in the body of people with nephrotic syndrome compared to healthy volunteers. It may help doctors understand the right dose for people with kidney issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You weigh more than 60 kg (about 132 pounds) and your body mass index is between 18.5 and 28.
- You either have nephrotic syndrome (with high protein in urine and low blood albumin) or you are a healthy volunteer with normal blood protein levels.
- Your kidney function is at least 50 ml/min (doctors can check this with a simple blood test).
- You have not had recent major bleeding, surgery, or trauma, and you are not at high risk for bleeding.
- You must be willing to stop taking certain medications (like blood thinners, some antidepressants, and certain antibiotics) for a while before the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new version of the blood-thinning drug enoxaparin (called a biosimilar) to the standard brand, Clexane. If you are a healthy adult, you might be eligible to participate, which helps ensure the new drug works the same way.
This trial tests whether the blood thinner rivaroxaban can prevent dangerous blood clots in people with a kidney condition called membranous nephropathy who have low albumin levels and are at high risk for clots.
This study looks at how a common blood thinner (enoxaparin) is processed in the body of ICU patients with kidney failure, including those on dialysis. The goal is to make sure the dose is safe and effective for preventing blood clots in this fragile group.
This trial tests whether a daily pill called edoxaban can prevent blood clots that sometimes form around a central venous catheter in people with cancer. If it works, it could lower the risk of a dangerous clot without major side effects.
This study tests whether adding a blood thinner called edoxaban to standard care can help prevent another stroke in people aged 75 or older who have had a stroke within the last year. It aims to see if this combination is safe and works better than standard care alone.
This study looks at how the blood thinner enoxaparin (Lovenox) is absorbed in people with severe obesity when injected into two different body areas. It aims to see if the standard preventive dose works well, potentially improving clot prevention for people your size.
Hear when a new Nephrotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.